VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ZURA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ZURAZura Bio Limited
$1.24$103M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ZURA logo

Zura Bio Limited

ZURA
NASDAQ · Immunology Biotech
$1.24
At close - Nov 13, 4:00 PM EST - USD
Market Cap$118M
P/E-1.7x
52W High$7.44
Volume4.24M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Pre-Revenue Cash Burn Accelerates Against Substantial Liquidity

Zura Bio is a clinical-stage biotechnology company with no revenue, where the investment thesis hinges entirely on the successful development and commercialization of its pipeline. The company's primary strength is its substantial cash position of $205.1M, which provides a significant runway to fund operations.

GrowthStable
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

ZURA price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-105% Peers

P/E is 105% below peer median

03

Market leadership

RS 3 · Lag

Laggard (Underperforming 97% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Jan 27

Market performance

Price History →

Trailing total returns as of 11/16/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ZURA-77.66%
S&P 500 (^GSPC)+10.42%
1-Year Return
ZURA-70.33%
S&P 500 (^GSPC)+12.25%
3-Year Return
ZURA-69.00%
S&P 500 (^GSPC)+71.37%
5-Year Return
ZURA-82.87%
S&P 500 (^GSPC)+61.39%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$69M-31.0% YoY
Free cash flow FY25
-$65M-130.6% YoY
Operating margin FY25
-
ROIC (FY25)-
Avg ROIC 5Y-35.9%
ROE (TTM)-54%
Piotroski Score1 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (42%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Oct 27, 2026
-$0.20+1.9%
vs -$0.20
—
vs —
Q3 2026
Aug 11, 2026
-$0.21-9.8%
vs -$0.19
—
vs —
Q2 2026
May 7, 2026
-$0.22-29.4%
vs -$0.17
—
vs —
Q2 2026
Mar 19, 2026
-$0.49-172.2%
vs -$0.18
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Business Wire·Oct 27, 2026
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on October 26, 2026, the Company granted inducement awards consisting of options to purchase up to 250,200 Class A Ordinary Shares (the “Options”) to five newly hired employees. These awa.

GuruFocus·Oct 27, 2026
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates

[url="]Zura Bio Limited[/url] (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully

Business Wire·Aug 31, 2026
Zura Bio to Participate in the Cantor Global Healthcare Conference

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conference: Cantor Global Healthcare Conference Location: New York, NY Fireside chat: Wednesday, September 9, 2026, at 9.

Defense World·Aug 27, 2026
Contrasting Zura Bio (NASDAQ:ZURA) and Soligenix (NASDAQ:SNGX)

Soligenix (NASDAQ: SNGX - Get Free Report) and Zura Bio (NASDAQ: ZURA - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Profitability This table compares Soligenix and Zura Bio's

Filtered for Zura Bio LimitedMore Headlines
04

Compare before deciding

Benchmark ZURA against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Zura Bio Limited (ZURA)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ZURA logoZURAZura Bio LimitedCurrent
$1.24$117.8M-1.69——-53.97%—
IMVT logoIMVTImmunovant, Inc.
$34.18$7.05B-13.88—-7173.52%-63.01%—
ARQT logoARQTArcutis Biotherapeutics, Inc.
$28.26$3.53B129.2891.34%5.88%14.18%—
KYMR logoKYMRKymera Therapeutics, Inc.
$127.57$10.49B-36.54-16.72%-341.87%-22.39%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$328.13$9.15B-26.64-100%—-29.41%—
ABBV logoABBVAbbVie Inc.
$295.03$521.26B50.518.57%15.68%—2.23%

Compare ZURA vs Peers

Zura Bio Limited (ZURA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IMVT

Most directly comparable listed peer for ZURA.

Scale Benchmark

vs LLY

Larger-name benchmark to compare ZURA against a more recognizable public peer.

Peer Set

Compare Top 5

vs IMVT, ARQT, KYMR, PRAX

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ZURA SEC Filings & Documents

Zura Bio Limited (ZURA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 17, 2026·SEC

Material company update

Aug 11, 2026·SEC

Material company update

Jul 1, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 19, 2026·SEC

FY 2025

Mar 25, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 11, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when ZURA posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ZURA Frequently Asked Questions

Zura Bio Limited (ZURA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is ZURA profitable?

No. Zura Bio Limited (ZURA) reported a net loss of $93.5M over the trailing twelve months.

Dividend & Returns
What is ZURA's return on equity?

Zura Bio Limited (ZURA) had a return on equity (ROE) of -54.0% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Zura Bio Limited's free cash flow?

Zura Bio Limited (ZURA) had negative free cash flow of $81.7M over the trailing twelve months.

What if you invested $1,000 in ZURA back in 2021?

Total return calculator · dividends reinvested · 5+ years of data

See returns →